{{Rsnum
|rsid=58597806
|Gene=UGT1A9
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Orientation=plus
|Chromosome=2
|position=233672700
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|Gene_s=UGT1A8,UGT1A9,UGT1A10
}}[[rs58597806]] (Asp256Asn/D256N) is a SNP within [[UGT1A9]] (UDP glucuronosyltransferase 1 family, polypeptide A9).

{{PMID|18816295}} reduced [[propofol]] glucuronidation - considerably lowered glucuronidation of mycophenolic acid, 1-naphthol, and naringenin. may be at risk adverse effects w/ propofol and other UGT1A9 substrate administration

{{PMID|12730278}} essentially non-functional with regard to SN-38 (7-ethyl-10-hydroxycamptothecin) glucuronidation, an active metabolite of [[irinotecan]]

{{PharmGKB
|RSID=rs58597806
|Name_s=UGT1A9: D256N
|Gene_s=UGT1A10, UGT1A7, UGT1A8, UGT1A9
|Feature=Intron, Intron, Intron, Exon/NonSyn
|Evidence=PubMed ID:18816295
|Annotation=A study in 100 healthy Japanese volunteers showed that carriers of D256N may be at risk of suffering adverse effects of propofol and other substrates that are primarily metabolized by UGT1A9. In in vitro analyses the K(m) of wild-type and D256N for propofol glucuronidation were 111.2 and 43.6 microM, respectively. The V(max) of D256N was 8.1% and the efficiencies (V(max)/K(m)) was 19.1% of the wild-type. The V(max) value of D256N variant for mycophenolic acid was only 9.5% of the wild-type.
|Drugs=propofol
|Drug Classes=XENOBIOTICS
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA162356082
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}